Key result
A cumulative daunorubicine dose of ≥120 mg/m2 significantly increased the risk of early cardiotoxicity in children with acute lymphoblastic leukemia (PR 1.161).
Why the study?
Anthracycline therapy increases survival in childhood acute lymphoblastic leukemia but compromises cardiovascular outcomes, making the identification of risk factors for early cardiotoxicity important.
What are the risk factors for early daunorubicin-induced cardiotoxicity in children with acute lymphoblastic leukemia?
Population
49 children diagnosed with ALL treated with Indonesian Childhood ALL Protocol 2013
Comparison
Risk factors including sex, age, risk stratification group, and cumulative dose
Design
Retrospective study
Follow-up
First year of anthracycline administration
Authors
Loading...
Age ≥4 years, high-risk status, and cumulative dose ≥120 mg/m² were associated with early cardiotoxicity; leaves open need for prospective validation before changing surveillance.
Observational (n=49)
No
What are the risk factors for early daunorubicin-induced cardiotoxicity in children with acute lymphoblastic leukemia?
Relative Risk: 1.161 (95% CI 1.019–1.332)
Absolute Event Rate: 13.9% vs 0%
p-value: p=0.001
Samosir et al. (2021) conducted an observational in Childhood Acute Lymphoblastic Leukemia (n=49). Cumulative daunorubicine dose ≥120 mg/m2 vs. Cumulative daunorubicine dose <120 mg/m2 was evaluated on Early cardiotoxicity (decline of LVEF > 10% with a final LVEF < 53% during the first year) (PR 1.161, 95% CI 1.019-1.332, p=0.001). A cumulative daunorubicine dose of ≥120 mg/m2 significantly increased the risk of early cardiotoxicity in children with acute lymphoblastic leukemia (PR 1.161).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: